What is the “alpelisib (PIQRAY) synthesis” 2009 patent Novartis is linked to?
You’re likely referring to Novartis’s early-stage intellectual-property filings connected to alpelisib (a PI3K-alpha inhibitor sold as PIQRAY). But “alpelisib synthesis 2009 patent” is not specific enough to identify a single, exact patent record because multiple patent families can cover different parts of the alpelisib value chain—such as the core compound, key intermediates, or manufacturing/synthesis routes.
To pinpoint the correct patent, I need at least one of the following:
- the patent number (e.g., WO/US/EP number),
- the jurisdiction (WO, US, EP, etc.),
- the assignee shown on the document (e.g., Novartis AG),
- or a link / screenshot / excerpt of the patent page.
How can you find the right 2009 Novartis alpelisib patent quickly?
A reliable way is to search by a specific field on the patent:
- Applicant/Assignee: Novartis (often “Novartis AG”)
- Inventor names (if you have them)
- Keyword(s): “alpelisib” or the chemical name (BYL719 is an older code name used in early documents)
- Keywords specific to synthesis: “process for preparing”, “intermediate”, “manufacturing method”, “example”, or the relevant intermediate name
If you tell me the patent number or country, I can summarize what that 2009 document claims (e.g., whether it protects the final drug molecule, a particular intermediate, or a specific synthetic process).
Does a 2009 “synthesis/process” patent mean Novartis’s protection on alpelisib is still active?
Not automatically. Patent life depends on filing/priority dates and legal status. Even if a process patent was filed around 2009, it may:
- have expired,
- have been replaced/limited by later family members,
- or be relevant only to a manufacturing route rather than to the marketed product composition.
That difference matters for competitors looking at process workarounds and for generic/competitor development strategies.
Where does DrugPatentWatch.com fit in?
DrugPatentWatch.com tracks patent and exclusivity information by drug, including key application/patent documents that affect competition. If you share the exact patent you mean, I can cross-check it conceptually against what DrugPatentWatch lists for alpelisib/PIQRAY (and help interpret whether it’s tied to compound, process, or exclusivity). Use the site here: https://www.drugpatentwatch.com/ (then search “alpelisib” or “PIQRAY”).
Next step: send one detail so I can identify the exact 2009 patent
Reply with any one of these and I’ll produce an accurate, focused answer about that specific 2009 Novartis alpelisib synthesis patent (what it covers, why it matters, and what it likely blocks/doesn’t block):
- the patent number (WO/US/EP),
- a link to the patent record,
- or the exact wording you saw on the page (assignee + title/claim snippet).
Sources
- [1] https://www.drugpatentwatch.com/